INNATE PHARMA EUR0.05 (IPHYF) Rating Increased to Buy at Zacks Investment Research
INNATE PHARMA EUR0.05 (NASDAQ:IPHYF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm presently has a $13.00 price objective on the stock. Zacks Investment Research’s price objective would indicate a potential upside of 11.21% from the stock’s current price.
According to Zacks, “Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. “
Separately, Leerink Swann restated a “buy” rating on shares of INNATE PHARMA EUR0.05 in a research report on Wednesday, August 17th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/innate-pharma-eur0-05-iphyf-rating-increased-to-buy-at-zacks-investment-research.html
INNATE PHARMA EUR0.05 (NASDAQ:IPHYF) traded down 1.68% during midday trading on Tuesday, hitting $11.69. 4,750 shares of the stock traded hands. The company’s 50-day moving average is $12.19 and its 200 day moving average is $12.76. The firm’s market cap is $629.82 million. INNATE PHARMA EUR0.05 has a 12-month low of $10.36 and a 12-month high of $16.08.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INNATE PHARMA EUR0.05 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INNATE PHARMA EUR0.05 and related companies with MarketBeat.com's FREE daily email newsletter.